Tumor Antigen by Immunoassay - CA 19-9

CA 19-9 immunoassay (NCD142) is covered for monitoring treatment response and for assessing residual or recurrent disease following surgery in patients with an established diagnosis of pancreatic or biliary ductal carcinoma. The test is not covered for diagnosing these cancers or for evaluating symptomatic patients as part of a diagnostic workup; testing frequency is as clinically necessary and claim documentation must show the established diagnosis and clinical purpose for testing.

"CA 19-9 immunoassay is covered when used to monitor the response to therapy in patients with an established diagnosis of pancreatic carcinoma."

Sign up to see full coverage criteria, indications, and limitations.